Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

A comparison of safety and clinical outcomes of 100 vs 160µ cap in patients undergoing ReLEx-small incision lenticule extraction (SMILE)

Poster Details

First Author: S. Ganesh INDIA

Co Author(s):    S. Brar   S. Pereira                 

Abstract Details


To determine the safety, efficacy and clinical outcomes in patients undergoing ReLEx-small incision lenticule extraction (SMILE) with cap thickness of 100 or 160 µ.


Nethradhama Super Speciality Eye Hospital, Bangalore


In this prospective, comparative, non-randomized clinical trial, a refractive lenticule of intrastromal corneal tissue was created with the VisuMax femtosecond laser system with a cap thickness of 100 or 160 µ. Hundred eyes of 50 eligible patients with low to moderate myopia of ≤ 6 D were treated. Minimum post-operative follow-up was 3 months.


At the end of three months post operatively, mean log-MAR UDVA, CDVA, spherical equivalent, total higher order aberrations, contrast sensitivity and subjective questionnaire showed no statistically significant differences (p > .05) between the two groups. Both the surgical procedures showed similar safety and efficacy indices with no loss of BCVA in either group. In dry eye assessment, TBUT in the 160 microns group was significantly better as compared to the 100 microns at 15 days, while at 90 days both groups had similar outcomes. Schirmers 1 and 2 values were also comparable in both groups.


Both the surgical procedures were equally safe and efficacious at the end of 3 months. However, dry eye assessment suggested that tear film stability may be better in160 micron cap group. Leaving a 160 micron cap may render the possibility of re-enhancement with ReLEx SMILE should the need arise in future.

Financial Disclosure:


Back to Poster listing